Hubei Historical Cash Flow
| 600566 Stock | 29.84 1.33 4.67% |
Analysis of Hubei Jumpcan cash flow over time is an excellent tool to project Hubei Jumpcan Pharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 234.7 M or Total Cash From Operating Activities of 3.6 B as it is a great indicator of Hubei Jumpcan ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Hubei Jumpcan Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hubei Jumpcan Pharma is a good buy for the upcoming year.
Hubei |
About Hubei Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Hubei balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Hubei's non-liquid assets can be easily converted into cash.
Hubei Jumpcan Cash Flow Chart
Add Fundamental
Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by Hubei Jumpcan Pharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Hubei Jumpcan operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Hubei Jumpcan Pharma financial statement analysis. It represents the amount of money remaining after all of Hubei Jumpcan Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Hubei Jumpcan's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Hubei Jumpcan Pharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Hubei Jumpcan Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Hubei Jumpcan's Dividends Paid is projected to increase significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 3.6 B, whereas Capital Expenditures is forecasted to decline to about 234.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 248.3M | 243.7M | 301.6M | 234.7M | Dividends Paid | 409.4M | 605.5M | 823.2M | 864.3M |
Hubei Jumpcan cash flow statement Correlations
Click cells to compare fundamentals
Hubei Jumpcan Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hubei Jumpcan cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividends Paid | 1.0B | 1.0B | 409.4M | 605.5M | 823.2M | 864.3M | |
| Capital Expenditures | 546.4M | 429.6M | 248.3M | 243.7M | 301.6M | 234.7M | |
| Total Cash From Operating Activities | 2.1B | 1.8B | 1.9B | 2.6B | 3.5B | 3.6B | |
| Net Income | 1.6B | 1.3B | 1.7B | 2.2B | 2.8B | 3.0B | |
| Total Cash From Financing Activities | (1.0B) | 373.8M | (361.2M) | (117.6M) | (105.8M) | (100.5M) | |
| Change To Inventory | (20.3M) | 60.0M | (97.2M) | (15.9M) | (98.6M) | (93.7M) | |
| Change To Account Receivables | 28.7M | 15.2M | (181.2M) | (713.7M) | (642.3M) | (610.2M) | |
| Other Cashflows From Investing Activities | 12.3M | 7.6M | 49.1M | 67.5M | 77.7M | 81.5M | |
| Investments | 89M | (1.1B) | (474.9M) | (1.4B) | (394.2M) | (413.9M) | |
| Change In Cash | 697.9M | 674.3M | 859.8M | 999.9M | 2.9B | 3.1B | |
| Net Borrowings | (538.0) | (172.0) | (1.8M) | 390.7M | 351.6M | 369.2M | |
| Total Cashflows From Investing Activities | (444.5M) | (1.5B) | (673.3M) | (1.5B) | (1.4B) | (1.3B) | |
| Depreciation | 232.5M | 281.0M | 293.8M | 303.9M | 302.7M | 240.4M | |
| Change To Operating Activities | (2.3M) | 31.2M | (6.2M) | (4.1M) | (4.7M) | (4.4M) | |
| Change To Netincome | 10.4M | 14.4M | (120.7M) | 4.2M | 3.8M | 4.0M | |
| Change To Liabilities | 273.1M | 95.6M | 276.4M | 861.3M | 990.4M | 1.0B | |
| End Period Cash Flow | 2.3B | 3.0B | 3.8B | 4.8B | 7.7B | 8.1B | |
| Free Cash Flow | 1.6B | 1.4B | 1.6B | 2.4B | 3.2B | 1.8B | |
| Change In Working Capital | 259.4M | 165.2M | (1.9M) | 131.7M | 404.7M | 424.9M | |
| Begin Period Cash Flow | 1.6B | 2.3B | 3.0B | 3.8B | 4.8B | 2.7B | |
| Other Non Cash Items | 33.3M | 40.1M | 45.2M | 39.9M | 19.6M | 34.9M |
Currently Active Assets on Macroaxis
Other Information on Investing in Hubei Stock
The Cash Flow Statement is a financial statement that shows how changes in Hubei balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Hubei's non-liquid assets can be easily converted into cash.